T he development of methods to transfer genetic material into the heart and vasculature of intact animals has opened new frontiers in both cardiovascular biology and therapeutics.' Gene transfer approaches are yielding insights into cardiovascular cell biology2 and may eventually allow the treatment of thrombosis, restenosis, and ischemic heart disease through the localized expression of therapeutic gene products. [3] [4] [5] [6] A technical hurdle that must be overcome before the initiation of cardiovascular gene therapies is the development of efficient and clinically useful methods to introduce genetic material into target cells. Lin et a16 and Acsadi et a17 both demonstrated in vivo gene transfer into rat myocardium using injection through a needle. The presence of inflammation, apparent myocyte necrosis, and scar tissue along the needle tracks in both studies raises questions about the applicability of this technique to human cardiac disease. Nabel et al8,9 described two potential methods for the introduction of genetically engineered cells into the vessel wall: 1) gene transfer into endothelial or smooth muscle cells in vitro followed by the introduction of these cells into the vessel wall of a recipient animal and 2) direct in vivo gene transfer into the vessel wall by injection of either retroviral vector or plasmid-containing solutions through a double balloon catheter.5 Both methods require total occlusion of the target vessel for 30 minutes while infusion of the solution (containing either cells or genes) takes place. This prolonged period of total occlusion may be problematic when applied to an end vessel supplying an ischemic territory, for example, a stenotic coronary artery.
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To provide a solution to the problem of prolonged occlusion during vascular gene transfer, we developed an in vivo gene transfer protocol using an iafusion balloon catheter. The infusion balloon catheter we used, first described by Wolinsky and Thung,10 was designed to allow drug delivery into the wall of a diseased human coronary artery within a clinically relevant time period. We used the Wolinsky infusion catheter to inject retroviral vector-containing virions into rabbit aortas. The efficiency and reliability of the 12 3) The B2NSt and SAX viral vectors, which express tissue plasminogen activator and adenosine deaminase, respectively, routinely yield viral stocks with titers approximately one log higher than those produced by LBgSN and B2NCL (data not shown). After adopting a detection system based on the presence of the neomycin phosphotransferase gene (see below), we used B2NSt and SAX to ensure that titer was optimized.
The construction of the B2NCL, B2NSt, and SAX vectors has been described previously.12-14 The LBgSN vector has a structure analogous to that of the BAG vector,15 containing the E. coli f-gal gene driven by the Moloney murine leukemia virus long terminal repeat and the neomycin phosphotransferase gene driven by a simian virus 40 promoter. The LBgSN vector was a kind gift of Genetic Therapy, Inc. (Gaithersburg, Md.).
Virion-containing supernatants were harvested from producer cells essentially as described16 and filtered through 0.22-,um filters. Titers of the supernatants used in these studies ranged from approximately 4x 104 to 6x 105 G418-resistant cfu/ml, as measured by their ability to transfer G418 resistance to 3T3 cells. All supernatants were tested and were found to be negative for the presence of replication-competent helper virus by the S+/L-assay.'7 Before injection of supernatants, protamine sulfate (Eli Lilly and Co., Indianapolis, Ind.) was added to a final concentration of 5 gg/ml to increase virion binding and transduction efficiency.'8 As a "vehicle" control in certain experiments, the same formulation of tissue culture medium as used to collect virions (Dulbecco's modified Eagle's medium with 10% fetal calf serum) was made to 5 gg/ml with protamine and injected into rabbit aortas exactly as described for virion-containing supernatant. In Vivo Gene Transfer Perforated balloon (Wolinsky) infusion catheters (3.25-4.0 mm in diameter, 20 mm long) were kindly provided by USCI, Inc. (Billerica, Mass.). Rabbits were sedated with ketamine and xylazine and maintained with halothane anesthesia by endotracheal tube. The left superficial femoral artery was exposed surgically, and the infusion balloon catheter was introduced through an arteriotomy. In 18 of the 34 rabbits that received injections, a midline laparotomy was also performed, the abdominal aorta was exposed, and virions were injected into the abdominal aortic wall under direct vision. We marked the segment of injected aorta with metal clips, allowing precise identification of the injected segment at death. In 16 rabbits injected under fluoroscopic guidance, the site of injection was localized by use of a grid and anatomical landmarks. Ten of these 16 rabbits received injections in both the thoracic and the abdominal aorta.
After the infusion balloon was positioned under either fluoroscopic guidance or direct vision, the solution of retroviral vector-containing virions was injected. Injection pressure was 5±1 atmospheres, with volumes of 5-10 ml injected over a period of 30 As a positive control and to allow a semiquantitative determination of the number of transduced cells present in tissue samples, aliquots of from 102 to 105 cultured rabbit endothelial cells transduced with the LBgSN vector were mixed with segments of aorta taken from rabbits that had never been exposed to retroviral vectors. DNA was extracted from these mixtures, amplified, and analyzed as described above.
Results

Injection of Virions In Vivo Through a Perforated Balloon Catheter
All rabbits survived the injection protocol without evidence of spinal cord or lower limb ischemia. When the rabbits were killed, all injected aortic segments were patent with no evidence of thrombosis.
Several pieces of data suggested that our injection protocol allowed the introduction of intact retroviral vector-containing virions into the rabbit aortic wall: 1) When Evans blue dye was injected through the catheter, we observed blue staining of the aorta in a pattern of 1-mm-diameter spots at the injection site corresponding to the distribution of holes in the infusion balloon.
Staining was also present both in the iliac artery and in the retroperitoneal space, suggesting that the infusion was not confined to the area of balloon inflation. 2) roscopic guidance, injection of contrast dye confirmed that blood flow was completely occluded distal to the inflated balloon. 3) When the virion injections were performed under direct vision, clear fluid was observed to accumulate on the adventitia of the aorta, consistent with penetration of the injectate through the vessel wall. 4) Histological analysis of injected aortas revealed occasional craterlike excavations, suggestive of contact with high-pressure injectate (Figure 2) .
To determine whether the catheter injection protocol was harmful to the virions, aliquots of virion-containing supernatant were injected through Wolinsky catheters into polypropylene tubes. Injected supernatants were then titered for their ability to transfer G418 resistance to 3T3 cells. The titer of catheter-injected supernatant was not significantly different from that of control (noninjected) supernatant (data not shown).
Detection of Gene Expression by X-Gal Staining
We anticipated that cells transduced with the f-galexpressing vector LBgSN would stain blue and that cells that were either not transduced or transduced with different vectors would remain colorless. Macroscopic examination of the lumina of X-Gal-stained aortas revealed blue staining (suggestive of f-gal gene expression) both in rabbits that received the LBgSN vector and in control rabbits that received either the non-flgal-expressing B2NSt vector (n=4) or vehicle only (n=5) (Figures 3A and 3B ). Virtually all of the aortas exhibited some blue staining, which was not confined to the areas of balloon infusion (Figure 2A ). The extent of blue staining was variable, both in the LBgSN-injected aortas and in the controls. In both experimental and control groups, individual aortas were found with either diffuse or rare blue staining. Frequent observations of the specimens during the period of incubation with X-Gal chromogen revealed no difference between experimental rabbits and controls in the rate of development of blue color.
Examination of microscopic sections of X-Galstained vessels also failed to differentiate experimental rabbits from controls in a definitive manner. Sections taken from X-Gal-stained aortas of nine rabbits that had received LBgSN injections and nine rabbits injected with either the non-fl-gal-expressing B2NSt vector (n = 4) or with a vehicle control (n = 5) were examined by two observers blinded to the injectate used. Blue cells experimental rabbits and in one of 13 controls (p<0.03 by Fisher's exact test). Positive PCR Southern blots were found with LBgSN (three of four), B2NCL (one of four), and B2NSt (two of three).
Comparison of the intensity of the radioactive bands produced by the samples with the intensity of bands produced by standards (see "Methods") permitted an estimate of the number of transduced cells in the tissue samples. The intensity of the radioactive bands of the experimental rabbits was in almost all cases less than that of the 102 cells per segment standard; it was never greater than the 10i cells per segment standard. Furthermore, in only one of the experimental rabbits did repeated amplifications of the extracted DNA always produce a detectable band (three positive amplifications of three). In five of the experimental rabbits, amplification of multiple aliquots of extracted DNA yielded both positive and negative results: two positive amplifications out of three in one rabbit, one of three in three rabbits, and one of four in one rabbit. This pattern of results is most consistent with the presence of very low numbers of transduced cells in the infused aortic segments. It is likely that each aortic segment contains fewer than 100 transduced cells, representing less than one in 10i total cells.
Aliquots of all of the samples of extracted aortic DNA were amplified with the ,B-globin primers, with the same PCR protocol as used for detection of the neomycin phosphotransferase sequences. All amplifications yielded a fragment of approximately 345 base pairs, easily visible on an ethidium bromide-stained agarose gel. The intensity of the ethidium-stained band produced from these 3-globin amplifications was virtually identical in all of the tissue samples (data not shown). These results indicate that the inability to detect ampli- 
